Cricut® Launches a New Category with the All-New Cricut StickerPix™ Line, Bringing Personalized Sticker Making into Its Creativity Platform

Cricut Inc. (CRCT) launched the Cricut Maker 5, a cutting and engraving machine with expanded capabilities. Q2 revenue fell 9% to $156.3M, but profit rose 59% to $39.1M. Subscriptions grew, with 3.1M paid subscribers and platform revenue up 5% to $85.0M. Hardware sales declined 22% to $71.3M, and user growth slowed.

Cricut, Inc. (CRCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Cricut, Inc. Reports Second Quarter 2026 Financial Results Over 3.1 million Paid Subscribers, up 3% over Q2 2025 Q2 2026 revenue of $156.3 million, down 9% compared to Q2 2025 Net income of $39.1 million, up 59% compared to Q2 2025 Recurring semi-annual dividend of $0.10 per shar

Microsoft unveiled new Surface Pro and Surface laptops with Qualcomm's Snapdragon Elite X2 chips, offering improved performance, battery life, and camera quality. The devices feature increased RAM options and superior webcams, according to Microsoft's Brett Ostrum. The chips' smartphone heritage enhances battery life and image processing, with Microsoft claiming top camera rankings from DxOMark.

Alaska Air expects Boeing's 737 MAX 10 to be certified by late September, with delivery of its first aircraft planned for spring 2024. The airline aims to start passenger service between April and mid-May, according to COO Jason Berry.

Roivant Sciences (ROIV) shares rose 17% after reporting positive Phase 2 results for mosliciguat, its experimental treatment for pulmonary hypertension. The drug met primary and secondary endpoints, reducing pulmonary vascular resistance by 56.3% and improving six-minute walk distance. J.P. Morgan estimates peak sales of $1.5B, though this is an analyst forecast. Roivant is now advancing to Phase 3 trials.

Inhibrx Biosciences reported that its experimental cancer drug INBRX-106, combined with Merck's Keytruda, achieved a 48.3% response rate in a Phase 2 study, nearly double Keytruda's 26.5% alone. The stock fell 8.8% to $110.45 despite the positive data, with the company planning to expand the study for HPV-positive patients, according to Reuters.